DOCSLIB.ORG

Irf1) Signaling Regulates Apoptosis and Autophagy to Determine Endocrine Responsiveness and Cell Fate in Human Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Irf1) Signaling Regulates Apoptosis and Autophagy to Determine Endocrine Responsiveness and Cell Fate in Human Breast Cancer INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER A Dissertation Submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Physiology & Biophysics By Jessica L. Roberts, B.S. Washington, DC September 27, 2013 Copyright 2013 by Jessica L. Roberts All Rights Reserved ii INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER Jessica L. Roberts, B.S. Thesis Advisor: Robert Clarke, Ph.D. ABSTRACT Interferon regulatory factor-1 (IRF1) is a nuclear transcription factor and pivotal regulator of cell fate in cancer cells. While IRF1 is known to possess tumor suppressive activities, the role of IRF1 in mediating apoptosis and autophagy in breast cancer is largely unknown. Here, we show that IRF1 inhibits antiapoptotic B-cell lymphoma 2 (BCL2) protein expression, whose overexpression often contributes to antiestrogen resistance. We proposed that directly targeting the antiapoptotic BCL2 members with GX15-070 (GX; obatoclax), a BH3-mimetic currently in clinical development, would be an attractive strategy to overcome antiestrogen resistance in some breast cancers. Inhibition of BCL2 activity, through treatment with GX, was more effective in reducing the cell density of antiestrogen resistant breast cancer cells versus sensitive cells, and this increased sensitivity correlated with an accumulation of autophagic vacuoles. While GX treatment promoted autophagic vacuole and autolysosome formation, p62/SQSTM1, a marker for autophagic degradation, levels accumulated. Moreover, GX exposure resulted in a reduction of cathepsin D and L protein expression that would otherwise digest autolysosome cargo. Taken together, these data highlight a new mechanism of GX- induced cell death that could be used to design novel therapeutic interventions for antiestrogen resistant breast cancer. iii In addition to establishing a functional role for BCL2 members downstream of IRF1, we also provided evidence that this IRF1 mediates antiestrogen sensitivity in breast cancer through autophagy signaling. We demonstrated that IRF1 and autophagy-related protein 7 (ATG7) expression were inversely correlated in vivo and in human breast cancer tissues. We then identified both ATG7 and the functionally related protein, beclin-1 (BECN1), as negative regulators of IRF1. Conversely, loss of IRF1 promoted antiestrogen resistance by increasing prosurvival autophagy, whereas combined ATG7 and IRF1 knockdown restored sensitivity to the antiestrogen fulvestrant (Faslodex, ICI 182780, ICI). Thus, inhibition of autophagy proteins, ATG7 and BECN1, enables IRF1- dependent and -independent signaling pathways and provides a novel therapeutic approach for inhibiting breast cancer cell proliferation. iv ACKNOWLEDGEMENTS I would first like to express my deepest appreciation to my mentor, Dr. Robert Clarke, for his continuous patience and support of my Ph.D. work, academic progress, and professional development. His positive attitude, creativity, and exceptional intellect continually inspired me with new ideas and motivated me to succeed as a cancer researcher. Without his guidance and persistent help this dissertation would not have been possible. I would also like to thank the members of his laboratory, especially Drs. Ayesha Shajahan-Haq and Katherine Cook for guiding my research and providing constant advice and encouragement. Assistance from the Hilakivi-Clarke and Riggins laboratories also proved invaluable and helped to make this dissertation possible. To the members of my committee, Drs. Ayesha Shajahan-Haq, Tom Sherman, Priscilla Furth, and Minetta Liu, thank you for all of your encouragement, insightful comments, and hard questions. I also thank my academic advisor, Dr. Kathryn Sandberg, for her guidance and support during my professional development. Lastly, this doctoral effort could not have been achieved without the support of my family and friends. Thanks to my parents, Kathy and Jerry Schwartz, for their persistent love and support. They built the foundation that allowed me to get this far and always encouraged me to work hard to achieve my goals. Without you, I would not be the person I am today. v Above all, I would like to thank my husband, Matt, for his unwavering love and support. Thank you for being my inspiration, editor, proofreader, and comic relief. But most of all, thank you for being my best friend. I could not have done this without you. Finally, this work would not have been possible without the financial support of a NRSA predoctoral fellowship provided by the National Cancer Institute of the National Institutes of Health (Award Number F31CA165514), for which I am extremely grateful. vi TABLE OF CONTENTS Chapter 1: Introduction 1.1 Breast Cancer Incidence and Risk Factors………………………………………….1 1.2 Endocrine Therapies for Breast Cancer…………………………………………….5 1.3 Antiestrogens……………………………………………………………………….7 1.4 Mechanisms of Antiestrogen Action……………………………………………….10 1.5 Cell Death and Antiestrogens………………………………………………………13 1.6 Antiestrogen Resistance……………………………………………………………15 1.7 Interferon Regulatory Factor-1 Mediates Antiestrogen Sensitivity………………..19 1.8 Hypothesis and Aims……………………………………………………………….20 Chapter 2: Effect of the BCL2 Inhibitor, GX15-070, on Apoptosis and Autophagy in Breast Cancer Cell Lines 2.1 Introduction…………………………………………………………………………22 2.1.1. Antiestrogen Resistance………………………………………………22 2.1.2. BCL2 Family Members……………………………………………….23 2.1.3. BH3 Mimetics…………………………………………………………24 2.1.4. Autophagy and Lysosomal Function………………………………….25 2.1.5. Normal Function of Lysosomes………………………………………26 2.1.6. Lysosomal Hydrolases………………………………………………..27 2.1.7. Cathepsin D…………………………………………………………...28 2.1.8. Cathepsins B and L……………………………………………………29 2.2 Materials and Methods……………………………………………………………...31 2.2.1. Cell Culture and Reagents…………………………………………….31 vii 2.2.2. Cell Proliferation……………………………………………………..31 2.2.3. RNA Interference…………………………………………………….32 2.2.4. Western Blot Analysis………………………………………………..32 2.2.5. Reverse Transcription PCR…………………………………………..32 2.2.6. Apoptosis and autophagosome formation assays…………………….33 2.2.7. Autophagosome Maturation………………………………………….33 2.2.8. Orthotopic xenografts in athymic nude mice………………………...34 2.2.9. Immunohistochemistry……………………………………………….34 2.2.10. Electron Microscopy…………………………………………………34 2.2.11. Cathepsin Activity…………………………………………………...35 2.2.12. Isolation of Cytosolic Enriched Fraction…………………………….35 2.2.13. Statistical Analysis…………………………………………………...35 2.3 Results……………………………………………………………………………...36 2.3.1. Breast cancer models for antiestrogen resistance……………………36 2.3.2. Endogenous BCL2 expression in breast cancer cell lines can be targeted with the BH3 mimetic, GX…………………………………38 2.3.3. GX alone and in combination with an antiestrogen inhibits breast cancer cell density through apoptosis………………………………..38 2.3.4. GX induces autophagosome formation………………………………42 2.3.5. GX induces BECN1-dependent autophagosome formation, but autophagy is not required for GX toxicity…………………………...42 2.3.6. GX induces autophagic vacuole and lysosome formation in antiestrogen resistant LCC9 breast cancer cells……………………..47 2.3.7. GX treatment results in the accumulation of LC3-II and p62 proteins………………………………………………………………47 viii 2.3.8. GX blocks autophagic degradation through attenuation of cathepsin activity…………………………………………………….50 2.3.9. Inhibition of cathepsin L and D results in breast cancer cell death by blocking autophagosomal degradation…………………………...58 2.4. Discussion………………………………………………………………………….61 2.4.1. GX inhibits breast cancer cell proliferation through caspase- and PARP-independent mechanisms……………………………………..61 2.4.2. GX-mediated autophagosome formation is dependent on BECN1 but independent of ATG7……………………………………………62 2.4.3. GX inhibits autophagic cargo degradation…………………………..64 2.4.4. GX blocks autophagic cargo degradation by inhibiting cathepsin D and L protein expression…………………………………………..64 Chapter 3: IRF1 Signaling Regulates the Switch between Apoptosis and Autophagy to Determine Endocrine Responsiveness and Breast Cancer Cell Fate 3.1 Introduction………………………………………………………………………...66 3.1.1. Structure of the IRF1 gene/protein…………………………………..66 3.1.2. Role of IRF1 in IFN signaling……………………………………….68 3.1.3. Regulation of IRF1 expression………………………………………69 3.1.4. Biological functions of IRF1………………………………………...70 3.1.5. Tumor suppressive activities of IRF1………………………………..71 3.1.6. IRF1 in breast cancer………………………………………………...72 3.1.7. IRF1 and antiestrogen sensitivity……………………………………73 3.1.8. IRF1 in glucose metabolism…………………………………………74 3.1.9. Interplay between various forms of cell death: apoptosis and autophagy……………………………………………………………75 3.1.10. Autophagy in immunity and inflammation………………………….75 ix 3.2 Materials and Methods…………………………………………………………….77 3.2.1. Cell culture, reagents, and small interfering RNA (siRNA) treatments…………………………………………………………….77 3.2.2. Lentiviral plasmid creation and infection; creation of stable cell lines…………………………………………………………………..78 3.2.3. Cell proliferation….………………………………………………….79 3.2.4. Microarray analysis…………………………………………………..79 3.2.5. Western blot analysis………………………………………………...79 3.2.6. Isolation of mitochondrial enriched fraction………………………....80 3.2.7. MMP, autophagosome formation, ROS, and glucose uptake assays...80 3.2.8. Autophagosome
Load more

Recommended publications
  • Analysis of Estrogen Receptor Isoforms and Variants in Breast Cancer Cell Lines
    EXPERIMENTAL AND THERAPEUTIC MeDICINE 2: 537-544, 2011 Analysis of estrogen receptor isoforms and variants in breast cancer cell lines MAIE AL-BADER1, CHRISTOPHER FORD2, BUSHRA AL-AYADHY3 and ISSAM FRANCIS3 Departments of 1Physiology, 2Surgery, and 3Pathology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait Received November 22, 2010; Accepted February 14, 2011 DOI: 10.3892/etm.2011.226 Abstract. In the present study, the expression of estrogen domain C, the DNA binding domain; domains D/E, bearing receptor (ER)α and ERβ isoforms in ER-positive (MCF7, both the activation function-2 (AF-2) and the ligand binding T-47D and ZR-75-1) and ER-negative (MDA-MB-231, SK-BR-3, domains; and finally, domain F, the C-terminal domain (6,7). MDA-MB-453 and HCC1954) breast cancer cell lines was The actions of estrogens are mediated by binding to ERs investigated. ERα mRNA was expressed in ER-positive and (ERα and/or ERβ). These receptors, which are co-expressed some ER-negative cell lines. ERα ∆3, ∆5 and ∆7 spliced in a number of tissues, form functional homodimers or variants were present in MCF7 and T-47D cells; ERα ∆5 heterodimers. When bound to estrogens as homodimers, the and ∆7 spliced variants were detected in ZR-75-1 cells. transcription of target genes is activated (8,9), while as heterodi- MDA-MB-231 and HCC1954 cells expressed ERα ∆5 and ∆7 mers, ERβ exhibits an inhibitory action on ERα-mediated gene spliced variants. The ERβ1 variant was expressed in all of the expression and, in many instances, opposes the actions of ERα cell lines and the ERβ2 variant in all of the ER-positive and (7,9).
    [Show full text]
  • Activated Peripheral-Blood-Derived Mononuclear Cells
    Transcription factor expression in lipopolysaccharide- activated peripheral-blood-derived mononuclear cells Jared C. Roach*†, Kelly D. Smith*‡, Katie L. Strobe*, Stephanie M. Nissen*, Christian D. Haudenschild§, Daixing Zhou§, Thomas J. Vasicek¶, G. A. Heldʈ, Gustavo A. Stolovitzkyʈ, Leroy E. Hood*†, and Alan Aderem* *Institute for Systems Biology, 1441 North 34th Street, Seattle, WA 98103; ‡Department of Pathology, University of Washington, Seattle, WA 98195; §Illumina, 25861 Industrial Boulevard, Hayward, CA 94545; ¶Medtronic, 710 Medtronic Parkway, Minneapolis, MN 55432; and ʈIBM Computational Biology Center, P.O. Box 218, Yorktown Heights, NY 10598 Contributed by Leroy E. Hood, August 21, 2007 (sent for review January 7, 2007) Transcription factors play a key role in integrating and modulating system. In this model system, we activated peripheral-blood-derived biological information. In this study, we comprehensively measured mononuclear cells, which can be loosely termed ‘‘macrophages,’’ the changing abundances of mRNAs over a time course of activation with lipopolysaccharide (LPS). We focused on the precise mea- of human peripheral-blood-derived mononuclear cells (‘‘macro- surement of mRNA concentrations. There is currently no high- phages’’) with lipopolysaccharide. Global and dynamic analysis of throughput technology that can precisely and sensitively measure all transcription factors in response to a physiological stimulus has yet to mRNAs in a system, although such technologies are likely to be be achieved in a human system, and our efforts significantly available in the near future. To demonstrate the potential utility of advanced this goal. We used multiple global high-throughput tech- such technologies, and to motivate their development and encour- nologies for measuring mRNA levels, including massively parallel age their use, we produced data from a combination of two distinct signature sequencing and GeneChip microarrays.
    [Show full text]
  • Expression of Estrogen Receptor-Beta Isoforms in Barrett's
    ANTICANCER RESEARCH 24: 2919-2924 (2004) Expression of Estrogen Receptor-Beta Isoforms in Barrett’s Metaplasia, Dysplasia and Esophageal Adenocarcinoma LIANG LIU, MINNI CHIRALA and MAMOUN YOUNES Departments of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, U.S.A. Abstract. We have previously shown that the majority of and beta (ER-B). ER-A is mainly expressed in female sex esophageal adenocarcinomas (EA), and its precursor Barrett’s organs, such as breast and uterus (2), whereas ER-B is metaplasia (BM), express estrogen receptor beta (ER-B). Several expressed in both sex organs and other tissues, such as isoforms of ER-B have been described and are presumed to have prostate, lung, thyroid, adrenal cortex and testis (3). Several different functions, but their distribution in BM and EA is not ER-B isoforms have been identified and characterized in known. The aim of this work was to determine which ER-B many non-gynecologic tumors including carcinomas of the isoforms are expressed in EA and BM. Sections of formalin-fixed lung (4), prostate (5), colon (6, 7) and stomach (8). and paraffin-embedded esophageal tissue from 33 esophageactomy Tamoxifen, a specific ER-B antagonist, has been successfully specimens, of which 27 had invasive EA, were stained for the ER- used in the treatment of patients with breast carcinoma B isoforms ER-B1, ER-B2, ER-B3 and ER-B5 utilizing the (9,10) and it has been shown that ER-B status is a significant immunoperoxidase method. ER-B1 was detected in 23 out of 27 predictor of survival in women with breast carcinoma treated (85%) EA compared to 3 out of 14 (21%) Barrett’s metaplasia with mastectomy and adjuvant tamoxifen (11).
    [Show full text]
  • Review Article the Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer
    SAGE-Hindawi Access to Research International Journal of Breast Cancer Volume 2011, Article ID 912102, 9 pages doi:10.4061/2011/912102 Review Article The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer J.L.Schwartz,A.N.Shajahan,andR.Clarke Georgetown University Medical Center, W401 Research Building, 3970 Reservoir Road, NW, Washington, DC 20057, USA Correspondence should be addressed to R. Clarke, [email protected] Received 18 February 2011; Revised 29 April 2011; Accepted 9 May 2011 Academic Editor: Chengfeng Yang Copyright © 2011 J. L. Schwartz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resistance to endocrine therapy is common among breast cancer patients with estrogen receptor alpha-positive (ER+) tumors and limits the success of this therapeutic strategy. While the mechanisms that regulate endocrine responsiveness and cell fate are not fully understood, interferon regulatory factor-1 (IRF1) is strongly implicated as a key regulatory node in the underlying signaling network. IRF1 is a tumor suppressor that mediates cell fate by facilitating apoptosis and can do so with or without functional p53. Expression of IRF1 is downregulated in endocrine-resistant breast cancer cells, protecting these cells from IRF1- induced inhibition of proliferation and/or induction of cell death. Nonetheless, when IRF1 expression is induced following IFNγ treatment, antiestrogen sensitivity is restored by a process that includes the inhibition of prosurvival BCL2 family members and caspase activation.
    [Show full text]
  • IFN-Α Wakes up Sleeping Hematopoietic Stem Cells
    NEWS AND VIEWS calcium consumption does not seem to have without increasing the risk of coronary heart 7. Aoki, K. et al. Ann. Epidemiol. 15, 598–606 (2005). such an effect. How to optimize calcium sup- disease, which has been associated with cal- 8. Langhans, N. et al. Gastroenterology 112, 280–286 13 plements for human health deserves further cium supplementation . (1997). investigation. 9. Recker, R.R. N. Engl. J. Med. 313, 70–73 (1985). 10. Yang, Y.-X. et al. J. Am. Med. Assoc. , 2947– Maybe it’s time to determine whether low- 1. Zaidi, M. Nat. Med. 13, 791–801 (2007). 296 2. Del Fattore, A. et al. Bone 42, 19–29 (2008). 2953 (2006). fat milk–based drinks taken as an alternative 3. Sobacchi, C. et al. Hum. Mol. Genet. 10, 1767–1773 11. Collazo-Clavell, M.L., Jimenez, A., Hodgson, S.F. & to the soda so frequently consumed, especially (2001). Sarr, M.G. Endocr. Pract. 10, 195–198 (2004). 4. Amling, M. et al. Nat. Med. 15, 674–681 (2009). 12. Bo-Linn, G.W. et al. J. Clin. Invest. 73, 640–647 during the early adolescent years, can attain 5. Straub, D.A. Nutr. Clin. Pract. 22, 286–296 (2007). (1984). the noble goal of keeping bones healthy— 6. Teitelbaum, S.L. Science 289, 1504–1508 (2000). 13. Bolland, M.J. BMJ 336, 262–266 (2008). IFN-α wakes up sleeping hematopoietic stem cells Emmanuelle Passegué & Patricia Ernst The cytokine interferon-α stimulates the turnover and proliferation of hematopoietic cells in vivo (pages 696–700).
    [Show full text]
  • The Proapoptotic Gene Interferon Regulatory Factor-1 Mediates the Antiproliferative Outcome of Paired Box 2 Gene and Tamoxifen
    Oncogene (2020) 39:6300–6312 https://doi.org/10.1038/s41388-020-01435-4 ARTICLE The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen 1 1 1 2 3 3 Shixiong Wang ● Venkata S. Somisetty ● Baoyan Bai ● Igor Chernukhin ● Henri Niskanen ● Minna U. Kaikkonen ● 4,5 2 6,7 Meritxell Bellet ● Jason S. Carroll ● Antoni Hurtado Received: 13 November 2019 / Revised: 5 August 2020 / Accepted: 17 August 2020 / Published online: 25 August 2020 © The Author(s) 2020. This article is published with open access Abstract Tamoxifen is the most prescribed selective estrogen receptor (ER) modulator in patients with ER-positive breast cancers. Tamoxifen requires the transcription factor paired box 2 protein (PAX2) to repress the transcription of ERBB2/HER2. Now, we identified that PAX2 inhibits cell growth of ER+/HER2− tumor cells in a dose-dependent manner. Moreover, we have identified that cell growth inhibition can be achieved by expressing moderate levels of PAX2 in combination with tamoxifen treatment. Global run-on sequencing of cells overexpressing PAX2, when coupled with PAX2 ChIP-seq, identified common targets regulated by both PAX2 and tamoxifen. The data revealed that PAX2 can inhibit estrogen-induced gene transcription 1234567890();,: 1234567890();,: and this effect is enhanced by tamoxifen, suggesting that they converge on repression of the same targets. Moreover, PAX2 and tamoxifen have an additive effect and both induce coding genes and enhancer RNAs (eRNAs). PAX2–tamoxifen upregulated genes are also enriched with PAX2 eRNAs. The enrichment of eRNAs is associated with the highest expression of genes that positivity regulate apoptotic processes.
    [Show full text]
  • A Dual Cis-Regulatory Code Links IRF8 to Constitutive and Inducible Gene Expression in Macrophages
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages Alessandra Mancino,1,3 Alberto Termanini,1,3 Iros Barozzi,1 Serena Ghisletti,1 Renato Ostuni,1 Elena Prosperini,1 Keiko Ozato,2 and Gioacchino Natoli1 1Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy; 2Laboratory of Molecular Growth Regulation, Genomics of Differentiation Program, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA The transcription factor (TF) interferon regulatory factor 8 (IRF8) controls both developmental and inflammatory stimulus-inducible genes in macrophages, but the mechanisms underlying these two different functions are largely unknown. One possibility is that these different roles are linked to the ability of IRF8 to bind alternative DNA sequences. We found that IRF8 is recruited to distinct sets of DNA consensus sequences before and after lipopolysaccharide (LPS) stimulation. In resting cells, IRF8 was mainly bound to composite sites together with the master regulator of myeloid development PU.1. Basal IRF8–PU.1 binding maintained the expression of a broad panel of genes essential for macrophage functions (such as microbial recognition and response to purines) and contributed to basal expression of many LPS-inducible genes. After LPS stimulation, increased expression of IRF8, other IRFs, and AP-1 family TFs enabled IRF8 binding to thousands of additional regions containing low-affinity multimerized IRF sites and composite IRF–AP-1 sites, which were not premarked by PU.1 and did not contribute to the basal IRF8 cistrome.
    [Show full text]
  • Transcription Factor IRF4 Drives Dendritic Cells to Promote Th2 Differentiation
    ARTICLE Received 30 May 2013 | Accepted 21 Nov 2013 | Published 20 Dec 2013 DOI: 10.1038/ncomms3990 Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation Jesse W. Williams1, Melissa Y. Tjota2,3, Bryan S. Clay2, Bryan Vander Lugt4, Hozefa S. Bandukwala2, Cara L. Hrusch5, Donna C. Decker5, Kelly M. Blaine5, Bethany R. Fixsen5, Harinder Singh4, Roger Sciammas6 & Anne I. Sperling1,2,5 Atopic asthma is an inflammatory pulmonary disease associated with Th2 adaptive immune responses triggered by innocuous antigens. While dendritic cells (DCs) are known to shape the adaptive immune response, the mechanisms by which DCs promote Th2 differentiation remain elusive. Herein we demonstrate that Th2-promoting stimuli induce DC expression of IRF4. Mice with conditional deletion of Irf4 in DCs show a dramatic defect in Th2-type lung inflammation, yet retain the ability to elicit pulmonary Th1 antiviral responses. Using loss- and gain-of-function analysis, we demonstrate that Th2 differentiation is dependent on IRF4 expression in DCs. Finally, IRF4 directly targets and activates the Il-10 and Il-33 genes in DCs. Reconstitution with exogenous IL-10 and IL-33 recovers the ability of Irf4-deficient DCs to promote Th2 differentiation. These findings reveal a regulatory module in DCs by which IRF4 modulates IL-10 and IL-33 cytokine production to specifically promote Th2 differentiation and inflammation. 1 Committee on Molecular Pathogenesis and Molecular Medicine, University of Chicago, 924 E. 57th Street, Chicago, Illinois 60637 USA. 2 Committee on Immunology, University of Chicago, 924 E. 57th Street, Chicago, Illinois 60637 USA. 3 Medical Scientist Training Program, University of Chicago, 924 E.
    [Show full text]
  • Common Single-Nucleotide Polymorphisms in the Estrogen Receptor B Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women
    Published OnlineFirst November 13, 2012; DOI: 10.1158/0008-5472.CAN-12-2484 Cancer Prevention and Epidemiology Research Common Single-Nucleotide Polymorphisms in the Estrogen Receptor b Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women Michael N. Passarelli1,2, Amanda I. Phipps1, John D. Potter1,2,3, Karen W. Makar1, Anna E. Coghill1,2, Karen J. Wernli3,4, Emily White1,2, Andrew T. Chan5,6, Carolyn M. Hutter1,2, Ulrike Peters1,2, and Polly A. Newcomb1,2 Abstract Loss of estrogen receptor b (ERb) expression in the gut is associated with colorectal cancer (CRC) initiation and progression. Germline single-nucleotide polymorphisms (SNP) in genes for the sex-steroid hormone receptors are not strongly associated with CRC risk; however, these SNPs have not previously been evaluated in relation to survival after diagnosis. We enrolled 729 women, ages 50 to 74, diagnosed with invasive CRC between 1997 and 2002 in 13 counties covered by the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry. Participants provided germline DNA. We selected 99 tag-SNPs for the androgen receptor (AR), ERa (ESR1), ERb (ESR2), and progesterone receptor (PGR) genes. Mortality outcomes were ascertained from the National Death Index. During a median of 6.6 years of follow-up, 244 deaths occurred (161 from CRC). We identified 20 SNPs (12 of ESR2 and 8 of PGR) for replication in 1,729 women diagnosed with incident invasive CRC (555 deaths; 405 from CRC) from three prospective cohort studies that participate in the Genetics and Epidemiology of Colorectal Cancer Consortium. Three correlated SNPs in the promoter of ESR2 (rs2987983, rs3020443, and rs2978381) were statistically significant predictors of CRC-specific and overall survival.
    [Show full text]
  • CDP/Cut Is the DNA-Binding Subunit of Histone Gene Transcription Cell
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 11516-11521, October 1996 Biochemistry CDP/cut is the DNA-binding subunit of histone gene transcription factor HiNF-D: A mechanism for gene regulation at the G1/S phase cell cycle transition point independent of transcription factor E2F (proliferation/gene expression/cyclin-dependent kinase/tumor suppressor) A. J. VAN WIJNEN*, M. F. vAN GURP*, M. C. DE RIDDER*, C. TUFARELLIt, T. J. LAST*, M. BIRNBAUM*, P. S. VAUGHAN*, A. GIORDANOt, W. KREK§, E. J. NEUFELDt, J. L. STEIN*, AND G. S. STEIN* *Department of Cell Biology, University of Massachusetts Medical School and Cancer Center, 55 Lake Avenue North, Worcester, MA 01655; tDivision of Hematology, Enders 720, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115; tInstitute for Cancer Research and Molecular Medicine, Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107; and §Friedrich-Miescher Institut, Postfach 2543, CH-4002 Basel, Switzerland Communicated by Sheldon Penman, Massachusetts Institute of Technology, Cambridge, MA, June 26, 1996 (received for review June 5, 1996) ABSTRACT Transcription of the genes for the human. 2/pl3O, and p107), CDKs, and cyclins A and E (14-17). histone proteins H4, H3,.H2A, H2B, and Hi is activated at the Variation in the composition of E2F containing multiprotein G1/S phase transition of the cell cycle. We have previously complexes may be functionally relevant for the timing and shown that the promoter complex HiNF-D, which interacts extent to which cell cycle controlled genes are activated or with cell cycle control elements in multiple histone genes, repressed. contains the key cell cycle factors cyclin A, CDC2, and a Expression of the genes for the histone proteins H4, H3, retinoblastoma (pRB) protein-related protein.
    [Show full text]
  • Induced IFN Regulatory Factor 1 Transcription Factor by Myd88 in Toll-Like Receptor-Dependent Gene Induction Program
    Evidence for licensing of IFN-␥-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program Hideo Negishi*, Yasuyuki Fujita*, Hideyuki Yanai*, Shinya Sakaguchi*, Xinshou Ouyang*, Masahiro Shinohara†, Hiroshi Takayanagi†, Yusuke Ohba*, Tadatsugu Taniguchi*‡, and Kenya Honda* *Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan; and †Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8549, Japan Contributed by Tadatsugu Taniguchi, August 18, 2006 The recognition of microbial components by Toll-like receptors (TLRs) In the present study we investigated how IFN-␥-induced IRF1 initiates signal transduction pathways, which trigger the expression contributes to TLR-mediated signaling. We demonstrate that of a series of target genes. It has been reported that TLR signaling is IRF1 forms a complex with MyD88, similar to the case of IRF4, enhanced by cytokines such as IFN-␥, but the mechanisms underlying IRF5, and IRF7. We also provide evidence that IRF1 induced this enhancement remain unclear. The MyD88 adaptor, which is by IFN-␥ is activated by MyD88, which we refer to as ‘‘licensing,’’ essential for signaling by many TLRs, recruits members of the IFN and migrates rapidly into the nucleus to mediate an efficient regulatory factor (IRF) family of transcription factors, such as IRF5 and induction of IFN-␤, iNOS, and IL-12p35. Our study therefore IRF7, to evoke the activation of TLR target genes. In this study we revealed that IRF1 is a previously unidentified member of the demonstrate that IRF1, which is induced by IFN-␥, also interacts with multimolecular complex organized via MyD88 and that the IRF1 and is activated by MyD88 upon TLR activation.
    [Show full text]
  • In Vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3 4 Clarissa S. Santoso1, Zhaorong Li2, Jaice T. Rottenberg1, Xing Liu1, Vivian X. Shen1, Juan I. 5 Fuxman Bass1,2 6 7 1Department of Biology, Boston University, Boston, MA 02215, USA; 2Bioinformatics Program, 8 Boston University, Boston, MA 02215, USA 9 10 Corresponding author: 11 Juan I. Fuxman Bass 12 Boston University 13 5 Cummington Mall 14 Boston, MA 02215 15 Email: [email protected] 16 Phone: 617-353-2448 17 18 Classification: Biological Sciences 19 20 Keywords: COVID-19, cytokine release syndrome, cytokine storm, drug repurposing, 21 transcriptional regulators 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 22 Abstract 23 Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing 24 hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators 25 of inflammatory cytokines involved in the COVID-19 CRS to identify candidate transcription 26 factors (TFs) for therapeutic targeting using approved drugs.
    [Show full text]